Guiyang Xintian PharmaceuticalLtd Past Earnings Performance
Past criteria checks 2/6
Guiyang Xintian PharmaceuticalLtd has been growing earnings at an average annual rate of 8.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 8.6% per year. Guiyang Xintian PharmaceuticalLtd's return on equity is 7%, and it has net margins of 7.7%.
Key information
8.3%
Earnings growth rate
8.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 8.6% |
| Return on equity | 7.0% |
| Net Margin | 7.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Guiyang Xintian PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 923 | 71 | 570 | 39 |
| 31 Dec 23 | 954 | 81 | 589 | 38 |
| 30 Sep 23 | 994 | 99 | 595 | 32 |
| 30 Jun 23 | 1,089 | 105 | 675 | 26 |
| 31 Mar 23 | 1,047 | 110 | 648 | 22 |
| 01 Jan 23 | 1,088 | 112 | 675 | 22 |
| 30 Sep 22 | 1,094 | 117 | 681 | 21 |
| 30 Jun 22 | 1,040 | 111 | 653 | 20 |
| 31 Mar 22 | 1,004 | 106 | 629 | 23 |
| 01 Jan 22 | 970 | 101 | 608 | 20 |
| 30 Sep 21 | 954 | 102 | 596 | 19 |
| 30 Jun 21 | 902 | 96 | 561 | 17 |
| 31 Mar 21 | 865 | 96 | 537 | 13 |
| 31 Dec 20 | 751 | 74 | 474 | 13 |
| 30 Sep 20 | 726 | 63 | 484 | 7 |
| 30 Jun 20 | 711 | 62 | 457 | 14 |
| 31 Mar 20 | 712 | 57 | 459 | 18 |
| 31 Dec 19 | 773 | 71 | 492 | 21 |
| 30 Sep 19 | 761 | 76 | 479 | 25 |
| 30 Jun 19 | 739 | 73 | 472 | 26 |
| 31 Mar 19 | 700 | 71 | 445 | 31 |
| 31 Dec 18 | 694 | 71 | 437 | 32 |
| 30 Sep 18 | 678 | 69 | 414 | 34 |
| 30 Jun 18 | 677 | 69 | 411 | 40 |
| 31 Mar 18 | 691 | 68 | 438 | 28 |
| 31 Dec 17 | 682 | 66 | 441 | 23 |
| 30 Sep 17 | 680 | 67 | 447 | 16 |
| 30 Jun 17 | 665 | 62 | 459 | 0 |
| 31 Mar 17 | 641 | 60 | 435 | 0 |
| 31 Dec 16 | 633 | 57 | 432 | 0 |
| 30 Sep 16 | 615 | 59 | 415 | 0 |
| 30 Jun 16 | 565 | 41 | 397 | 0 |
| 31 Mar 16 | 536 | 41 | 378 | 0 |
| 31 Dec 15 | 522 | 42 | 367 | 0 |
| 30 Sep 15 | 509 | 44 | 356 | 0 |
| 30 Jun 15 | 496 | 47 | 345 | 0 |
| 31 Mar 15 | 475 | 40 | 331 | 0 |
| 31 Dec 14 | 454 | 33 | 317 | 0 |
| 31 Dec 13 | 406 | 15 | 288 | 0 |
Quality Earnings: 002873 has high quality earnings.
Growing Profit Margin: 002873's current net profit margins (7.7%) are lower than last year (10.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002873's earnings have grown by 8.3% per year over the past 5 years.
Accelerating Growth: 002873's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002873 had negative earnings growth (-35.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.6%).
Return on Equity
High ROE: 002873's Return on Equity (7%) is considered low.